General Information of Drug (ID: DM0PFNC)

Drug Name
AZD6738 Drug Info
Indication
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Phase 2 [1]
Chronic lymphocytic leukaemia 2A82.0 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
Cross-matching ID
PubChem CID
54761306
TTD Drug ID
DM0PFNC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RP-3500 DM9FNC8 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
Camonsertib DMOPPXY Aggressive cancer 2A00-2F9Z Phase 1/2 [6]
BAY1895344 DML781M Lymphoma 2A80-2A86 Phase 1 [3]
VX-970 DMR9PCT Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
M4344 DMQBO3V Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
M1774 DMP8QY2 Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
CGK733 DM8OAN9 Discovery agent N.A. Investigative [9]
AZ20 DMNQ3HV Discovery agent N.A. Investigative [10]
VE-821 DM0UXNF Solid tumour/cancer 2A00-2F9Z Investigative [7]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine/threonine-protein kinase ATR (FRP1) TT8ZYBQ ATR_HUMAN Inhibitor [4]

References

1 ClinicalTrials.gov (NCT03428607) Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01955668) AZD6738 First Time in Patient Multiple Ascending Dose Study. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 National Cancer Institute Drug Dictionary (drug id 754022).
5 Clinical pipeline report, company report or official report of Repare Therapeutics.
6 Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023 Jun;29(6):1400-1411.
7 ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
8 National Cancer Institute Drug Dictionary (drug name M1774).
9 Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74.
10 Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013 Mar 14;56(5):2125-38.